PI3K

Phosphoinositide 3-kinases (PI3Ks) are lipid kinases that catalyze the phosphorylation of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) to generate the second messenger phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P₃). The production of PI(3,4,5)P₃ facilitates the recruitment and activation of pleckstrin homology (PH) domain–containing proteins at the plasma membrane, thereby initiating downstream signaling cascades essential for cellular proliferation, survival, and migration.

PI3Ks are divided into three major classes, among which Class I PI3Ks are most prominently implicated in cancer biology. Class I enzymes comprise four distinct catalytic isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.

Class IA PI3Ks, the subclass most commonly associated with oncogenic signaling, function as heterodimeric lipid kinases composed of a catalytic p110 subunit (p110α, p110β, or p110δ, encoded by PIK3CA, PIK3CB, and PIK3CD, respectively) and a regulatory p85 subunit.

The PI3K signaling pathway plays a central role in diverse biological processes, including cell cycle progression, cellular growth, survival, actin cytoskeletal rearrangement, migration, and intracellular vesicular trafficking.

Frequently Asked Questions
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol lipids to regulate cell growth, survival, metabolism, and immune signaling. PI3K activation leads to downstream AKT and mTOR pathway signaling. Aberrant PI3K signaling is frequently observed in cancer due to PIK3CA mutations, PTEN loss, or receptor tyrosine kinase activation.
Class I PI3Ks include four catalytic isoforms: PI3Kα (PIK3CA) PI3Kβ (PIK3CB) PI3Kδ (PIK3CD) PI3Kγ (PIK3CG) PI3Kα and β are broadly expressed, while PI3Kδ and γ are enriched in leukocytes and play critical roles in immune regulation. Isoform selectivity is an important consideration in drug development due to toxicity and immune effects.
PI3K inhibitors can be classified as: Pan-PI3K inhibitors Isoform-selective inhibitors (α, β, δ, γ) Dual PI3K/mTOR inhibitors Irreversible inhibitors Selectivity influences therapeutic window and toxicity profile.
While PI3K inhibitors block upstream lipid kinase activity, mTOR inhibitors act downstream at the level of mTORC1 or mTORC2. Dual PI3K/mTOR inhibitors target both nodes of the pathway and may achieve broader pathway suppression.

Items 76-100 of 411

  • CAL-130
    Cat. No.
    A15030

    CAL-130

    CAL-130 is a novel phosphoinositide 3-kinase (PI3K) inhibitor. It is reported that combined inhibition of PI3Kδ/γ as therapy for T cell acute lymphoblastic leukemia (T-ALL).

    5 mg
    $500.00
    10 mg
    $800.00
    All 5 sizes
  • CAL-130 Hydrochloride
    Cat. No.
    A15031

    CAL-130 Hydrochloride

    CAL-130 Hydrochloride is a novel phosphoinositide 3-kinase (PI3K) inhibitor. It is reported that combined inhibition of PI3Kδ/γ as therapy for T cell acute lymphoblastic leukemia (T-ALL).

    2 mg
    $120.00
    5 mg
    $220.00
    All 7 sizes
  • LY 303511
    Cat. No.
    A15147

    LY 303511

    LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.

    5 mg
    $90.00
    10 mg
    $140.00
    All 6 sizes
  • NVP-BKM120 Hydrochloride (Buparlisib HCl)
    Cat. No.
    A15195

    NVP-BKM120 Hydrochloride (Buparlisib HCl)

    Synonyms: BKM-120 hydrochloride

    NVP-BKM120 Hydrochloride is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively. Reduced potency against VPS34, mTOR, DNA-PK, with little activity to PI4Kβ.

    2 mg
    $30.00
    5 mg
    $55.00
    All 5 sizes
  • PI-103 Hydrochloride
    Cat. No.
    A15212

    PI-103 Hydrochloride

    PI103 is a potent inhibitor with low IC50 values against recombinant PI3K isoforms p110alpha (IC50= 2 nM), p110beta (IC50= 3 nM), p110delta (IC50= 3 nM), and p110gamma (IC50= 15 nM), less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

    2 mg
    $30.00
    5 mg
    $60.00
    All 6 sizes
  • Pilaralisib
    Cat. No.
    A15283

    Pilaralisib (XL-147)

    Synonyms: SAR245408; XL 147

    XL147 is a potent, orally bioavailable inhibitor of the class I PI3K family of lipid kinases.

    2 mg
    $40.00
    5 mg
    $55.00
    All 7 sizes
  • Serabelisib
    Cat. No.
    A15529

    Serabelisib (MLN1117)

    Synonyms: INK1117; MLN 1117; TAK-117

    MLN1117, also known as INK1117 and TAK-117, is an orally bioavailable inhibitor of the class I phosphoinositide 3-kinase (PI3K) alpha isoform with potential antineoplastic activity.

    1 mg
    $30.00
    2 mg
    $45.00
    All 9 sizes
  • Ginsenoside Rk1
    Cat. No.
    A15674

    Ginsenoside Rk1

    Ginsenoside Rk1, one of the main elements of Sung Ginseng, has been confirmed as a new endothelial barrier enhancer recently and has anti-cancer activity.

    5 mg
    $85.00
    10 mg
    $150.00
    All 5 sizes
  • AZD8186
    Cat. No.
    A15759

    AZD8186

    AZD8186 is an isoform-specific small-molecule PI3K inhibitor, potently inhibits PI3Kβ (IC50=4 nM) and PI3Kδ (IC50=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM).

    2 mg
    $30.00
    5 mg
    $55.00
    All 8 sizes
  • VPS34-IN1
    Cat. No.
    A15874

    VPS34-IN1

    Synonyms: PS34 IN1

    Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.

    1 mg
    $30.00
    2 mg
    $45.00
    All 8 sizes
  • AMG319
    Cat. No.
    A15901

    AMG319

    AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.

    2 mg
    $35.00
    5 mg
    $60.00
    All 7 sizes
  • Bimiralisib
    Cat. No.
    A15992

    Bimiralisib (PQR309)

    Synonyms: PQR-309

    PQR309 is an orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity.

    1 mg
    $25.00
    2 mg
    $45.00
    All 8 sizes
  • ON 146040
    Cat. No.
    A16266

    ON 146040

    ON 146040 is the first dual PI3K and BCR-ABL inhibitor that targets the STAT3 and STAT5 pathways; inhibits PI3K α/δ isoforms with IC50 of 14/20 nM.

    1 mg
    $50.00
    5 mg
    $140.00
    All 7 sizes
  • PI4KIIIbeta-IN-9
    Cat. No.
    A16270

    PI4KIIIbeta-IN-9

    PI4KIIIbeta-IN-9 is a potent PI4KIIIbeta inhibitor (IC50 of 7 nM) and is >140-fold selective over PI3Kgamma and >20-fold selective over PI3Kδ, and shows no inhibition of vps34 at concentrations up to 20 uM.

    1 mg
    $65.00
    5 mg
    $190.00
    All 6 sizes
  • ETP-46321
    Cat. No.
    A16271

    ETP-46321

    ETP-46321 is a potent and orally bioavailable PI3K α/δ inhibitor with potent biochemical and cellular activity and good pharmacokinetic properties (PK) after oral dosing.

    1 mg
    $40.00
    5 mg
    $105.00
    All 8 sizes
  • Paxalisib
    Cat. No.
    A16272

    Paxalisib (GDC-0084)

    Synonyms: RG7666; GDC-0084

    GDC-0084 is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.

    1 mg
    $20.00
    2 mg
    $30.00
    All 7 sizes
  • PI3K-alpha inhibitor 1
    Cat. No.
    A16274

    PI3K-alpha inhibitor 1

    PI3Kα inhibitor 1 is a PI3Kα inhibitor extracted from patent US/20120088764A1, compound 243, has an IC50 < 0.1 uM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 uM ??? IC50 ??? 1 uM) .

    1 mg
    $115.00
    2 mg
    $170.00
    All 9 sizes
  • Voxtalisib
    Cat. No.
    A16276

    Voxtalisib (SAR245409, XL765)

    Synonyms: XL765; SAR 245409

    SAR245409 is a PI3K/mTOR dual kinase inhibitor XL765 is an orally bioavailable small molecule targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) kinases in the PI3K/mTOR signaling pathway, with potential antineoplastic activity.

    1 mg
    $25.00
    2 mg
    $40.00
    All 8 sizes
  • Umbralisib
    Cat. No.
    A16277

    Umbralisib (TGR-1202)

    Synonyms: RP5264; TGR1202

    TGR-1202 is an orally available, next generation PI3Kδ inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.

    1 mg
    $35.00
    2 mg
    $50.00
    All 8 sizes
  • TGR-1202 hydrochloride (Umbralisib HCl)
    Cat. No.
    A16278

    TGR-1202 hydrochloride (Umbralisib HCl)

    Synonyms: RP5264 hydrochloride; TGR1202 hydrochloride

    TGR-1202 hydrochloride is an orally available, next generation PI3Kδ inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.

    2 mg
    $45.00
    5 mg
    $100.00
    All 6 sizes
  • GSK2292767
    Cat. No.
    A16564

    GSK2292767

    GSK2292767 is a potent and selective inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ; Ki = 79 pM). GSK2292767 is >100-fold selective for PI3Kδ over a panel of 250 kinases.

    1 mg
    $105.00
    5 mg
    $180.00
    All 4 sizes

Items 76-100 of 411

Added to your cart

View Cart Checkout

    Loading...